The government shutdown in December and January has caused a tremendous backlog of quarterly and year-end filings for review at the SEC. Accordingly, our updated RegA+ Offering […]
The government shutdown in December and January has caused a tremendous backlog of quarterly and year-end filings for review at the SEC. Accordingly, our updated RegA+ Offering […]
I hope this note finds you off to a great 2019. We are pleased to announce that InSitu Biologics Stock Offering will again open on Wednesday, January […]
WOODBURY, Minn., Dec. 4, 2018 /Press Release/ — InSitu Biologics, Inc., an emerging biotech company focusing on the development of AnestaGel™, has received over $2 million in […]
Our Tier 3 of 30,000 shares is nearly full and we will pause our Stock Offering on Tuesday, November 27, 2018. At that time we plan on […]
Quick update for shareholders and prospective investors. We closed our Tier 2 $6.85 level with 43,126 shares sold. The SEC approved our Tier 3 with another share […]
This is Jim Segermark, CEO and Co-Founder of InSitu Biologics. Quick note to share our progress and upcoming events with you. If you live, or happen to […]